Search results
Showing 91 to 99 of 99 results for methotrexate
Secukinumab for treating moderate to severe plaque psoriasis (TA350)
Evidence-based recommendations on secukinumab (Cosentyx) for treating plaque psoriasis in adults.
Omalizumab for previously treated chronic spontaneous urticaria (TA339)
Evidence-based recommendations on omalizumab (Xolair) for treating severe chronic spontaneous urticaria in people of 12 and over.
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Evidence-based recommendations on ruxolitinib (Jakavi) for treating acute graft versus host disease that has an inadequate response to corticosteroids in people 12 years and over.
Show all sections
Evidence-based recommendations on enfortumab vedotin (Padcev) with pembrolizumab (Keytruda) for untreated unresectable or metastatic urothelial cancer in adults when platinum-based chemotherapy is suitable.
Evidence-based recommendations on belumosudil (Rezurock) for chronic graft-versus-host disease in people 12 years and over after 2 or more systemic treatments.
Find out more about NICE technology appraisals advisory committee D members
Nintedanib for treating progressive fibrosing interstitial lung diseases (TA747)
Evidence-based recommendations on nintedanib for treating progressive fibrosing interstitial lung diseases in adults.
NICE recommends several treatment options to help with rheumatoid arthritis
Around 25,000 people with moderate rheumatoid arthritis that has not responded to conventional therapies are set to benefit from the recommendations announced today.